Lysine demethylase 4B (KDM4B) degradation in breast cancer cells is also mediated by FBXO22, leading to modulation of selective estrogen receptor modulator (SERM) activity and thus tamoxifen resistance in estrogen receptor (ER)-positive breast cancer cells (5). Here, FBXO22 is linked to breast cancer.